Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit

• Dapaglilfozin, an SGLT2 inhibitor, increases the risk of genital fungal infections. • Women are at much greater risk of developing genital infections with dapagliflozin. • Patients with prior genital fungal infection are also at greater risk. • Higher baseline HbA1c or BMI did not increase treatme...

Description complète

Détails bibliographiques

Publié dans:	A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients. - 2016. - Amsterdam [u.a.]
Auteur principal:	Thong, Ken Yan (Auteur)
Autres auteurs:	Yadagiri, Mahender (Autre), Barnes, Dennis Joseph (Autre), Morris, David Stuart (Autre), Chowdhury, Tahseen Ahmad (Autre), Chuah, Ling Ling (Autre), Robinson, Anthony Michael (Autre), Bain, Stephen Charles (Autre), Adamson, Karen Ann (Autre), Ryder, Robert Elford John (Autre)
Format:	Article en ligne
Langue:	English
Publié:	2018
Accès à la collection:	A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients
Sujets:	Genital fungal infection Dapagliflozin Thrush SGLT2 inhibitor Genital mycotic infection
Description matérielle:	6